Pandey Saumya, Agrawal Devendra K
Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska 68178, USA.
Immunol Cell Biol. 2006 Aug;84(4):333-41. doi: 10.1111/j.1440-1711.2006.01444.x.
Toll-like receptors (TLR), a family of evolutionarily conserved pathogen recognition receptors, play pivotal role as primary sensors of invading pathogens. TLR identify molecular motifs of infectious agents (pathogen associated molecular patterns) and elicit an effective defensive response against them. Mammalian TLR derive their name from the Drosophila Toll protein, with which they share sequence similarity. So far, expression of 10 TLR is known in humans. The adaptor proteins, myeloid differentiation factor 88 and Toll IL-1 receptor (TIR) domain containing adaptor inducing IFN-beta (TRIF) are the key players in the TLR signalling cascade leading to the activation of nuclear factor (NF)-kappaB and interferon regulatory factor-3, respectively. Targeted manipulation of the TLR signalling pathway has immense therapeutic potential and may eventually prove to be a boon in the development of innovative treatments for diverse disease conditions. There is accumulating evidence that TLR agonists have tremendous potential as novel therapeutic targets. In this review, we have discussed the immunobiology of TLR and emphasize significant advances made within the ever-expanding field of TLR that provide intriguing insights efficacious in unravelling the complexities associated with TLR.
Toll样受体(TLR)是一类进化上保守的病原体识别受体,作为入侵病原体的主要传感器发挥关键作用。TLR识别感染因子的分子基序(病原体相关分子模式)并引发针对它们的有效防御反应。哺乳动物的TLR得名于果蝇的Toll蛋白,它们与该蛋白具有序列相似性。到目前为止,已知人类中有10种TLR表达。衔接蛋白髓样分化因子88和含Toll白细胞介素-1受体(TIR)结构域的衔接蛋白诱导干扰素-β(TRIF)分别是导致核因子(NF)-κB和干扰素调节因子-3激活的TLR信号级联反应中的关键参与者。对TLR信号通路进行靶向操纵具有巨大的治疗潜力,最终可能会被证明是开发针对各种疾病状况的创新疗法的福音。越来越多的证据表明,TLR激动剂作为新型治疗靶点具有巨大潜力。在这篇综述中,我们讨论了TLR的免疫生物学,并强调了在不断扩展的TLR领域取得的重大进展,这些进展为揭示与TLR相关的复杂性提供了有趣的见解。